Karihtala, P. (2025). How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?. Acta Oncologica, 64, 815–829. https://doi.org/10.2340/1651-226X.2025.43645